natgillin/translations-raw huggingface dataset:
Can be stored at room temperature (up to 30°C) for a single period up to 6 months.
Lahko hranite pri sobni temperaturi (do 30 °C) za enkratno obdobje največ 6mesecev.
Can be stored at room temperature C for a single period up to 6 months Taken out of refrigerator:
Zdravilo je lahko shranjeno pri sobni temperaturi (≤ 30 °C) za enkratno obdobje, ki ni daljše od 9 mesecev.
Can be stored at room temperature ≤30°C for a single period up to 6 months Taken out of refrigerator:
Zdravilo je lahko shranjeno pri sobni temperaturi (≤ 30 °C) za enkratno obdobje, ki ni daljše od 9 mesecev.
Can be stored in a refrigerator (2°C – 8°C).
Shranjujete lahko tudi v hladilniku (2 °C – 8 °C).
Can be stored short-term in a refrigerator at 2°C–8°C for up to 8 weeks prior to use.
Za kratek čas se lahko shrani v hladilniku pri temperaturi med 2 °C in 8 °C do 8 tednov pred uporabo.
Can be used as a booster for kittens or cats previously vaccinated with FELIGEN RCP and LEUCOGEN separately.
Se lahko uporabi kot poživilni odmerek za mačje mladiče in mačke, ki so bile predhodno cepljene posebej z zdraviloma FELIGEN CRP in LEUCOGEN.
Can be used during pregnancy and lactation
Lahko se uporablja v obdobju brejosti in laktacije.
Can be used during pregnancy and lactation in cows
Lahko se uporablja v obdobju brejosti pri ovcah.
Can be used during pregnancy and lactation or lay.
Lahko se uporablja v obdobju brejosti, laktacije ali nesnosti.
Can be used during pregnancy in ewes and cows.
Lahko se uporablja v obdobju brejosti ovc in krav.
Can be used during pregnancy in ewes.
Lahko se uporablja v obdobju brejosti in laktacije pri kravah.
Can be used during pregnancy, lactation or lay.
Lahko se uporablja v obdobju brejosti, laktacije in nesnosti
Can be used during pregnancy.
Lahko še uporablja v obdobju brejosti.
Can be used in breeding sheep including pregnant and lactating ewes.
Lahko se uporablja pri vzrejnih ovcah, tudi v obdobju brejosti in laktacije.
Can be used in breeding, pregnant and lactating dogs.
Zdravilo se lahko uporablja pri psih za vzrejo v obdobju brejosti in laktacije.
Can be used in breeding, pregnant and lactating dogs.
Zdravilo za uporabo v veterinarski medicini se lahko uporablja pri psih za vzrejo v obdobju brejosti in laktacije.
Can be used in pregnancy and lactation
Lahko se uporablja v obdobju brejosti in laktacije.
can be used without dose
didanozinom se lahko uporablja
can be used without dose
dolutegravirjem se lahko uporablja
can be used without dose
odmerkom ritonavirja lahko
can be used without dose
raltegravir se lahko
can be used without dose
uporablja brez prilagajanja
can be used without dose
uporabljata brez prilagajanja
can be used without dose adjustment.
brez prilagajanja odmerkov.
can be used without dose adjustments.
didanozinom se lahko uporablja
Can Guasc, 2 - Parets del Vallès 08150 Barcelona - Spain
Can Guasc, 2 - Parets del Vallès 08150 Barcelona – Španija
Canada (Quebec)4
Kanada (Quebec)4 (2004)
Canagliflozin + insulin
kanagliflozin + insulin
Canagliflozin + metformin and sulphonylurea
kanagliflozin + metformin in sulfonilsečnina
Canagliflozin as add-on therapy to insulin (with or without other glucose-lowering medicinal products).
Kanagliflozin kot dodatek k zdravljenju z insulinom (skupaj z drugimi antihiperglikemičnimi zdravili ali brez njih)
Canagliflozin does not exhibit time-dependent pharmacokinetics, and accumulated in plasma up to 36% following multiple doses of 100 mg and 300 mg.
Farmakokinetika kanagliflozina ni odvisna od časa odmerjanja, po večkratnih odmerkih 100 mg in 300 mg pa je prišlo do kopičenja kanagliflozina v plazmi v obsegu do 36%.
Canagliflozin was compared to glimepiride as dual therapy with metformin and compared to sitagliptin as triple therapy with metformin and a sulphonylurea (table 5).
Kanagliflozin so primerjali z glimepiridom v okviru dvotirnega zdravljenja z metforminom, s sitagliptinom v okviru trotirnega zdravljenja z metforminom in s sulfonilsečnino (preglednica 5).
canagliflozin works by blocking a protein in the kidneys called sodium glucose co-transporter 2 (SGLT2).
kanagliflozin zavira beljakovino v ledvicah, imenovano natrijev glukozni koprenašalec 2 (SGLT2).
canagliflozin/metformin hydrochloride
kanagliflozin/metforminijev klorid
Canagliflozin’s action to increase UGE directly lowering plasma glucose is independent of insulin.
Delovanje kanagliflozina na povečanje izločanja glukoze z urinom, s čimer neposredno zmanjša koncentracijo glukoze v plazmi, je neodvisno od insulina.
Canagliflozin’s action to increase UGE directly lowering plasma glucose is independent of insulin.
Delovanje kanagliflozina na povečanje izločanja glukoze z urinom, s čimer neposredno zniža koncentracijo glukoze v plazmi, je neodvisno od insulina.
Canakinumab binds with high affinity specifically to human IL-1 beta and neutralises the biological activity of human IL-1 beta by blocking its interaction with IL-1 receptors, thereby preventing IL-1 beta-induced gene activation and the production of inflammatory mediators.
Kanakinumab se z veliko afiniteto specifično veže na človeški interlevkin-1 beta in onemogoča njegovo biološko delovanje tako, da zavira njegovo interakcijo z receptorji za IL-1, s tem pa prepreči z IL-1 beta sproženo aktivacijo genov in tvorbo vnetnih mediatorjev.
Canakinumab has been designed to attach to a messenger molecule or ‘cytokine’ in the body called interleukin-1 beta.
Kanakinumab je bil zasnovan tako, da se veže na sporočilno molekulo ali citokin v telesu, ki se imenuje interlevkin-1 beta.
Canakinumab is a fully human monoclonal anti-human interleukin-1 beta (IL-1 beta) antibody of the
Kanakinumab je povsem človeško monoklonsko protitelo proti človeškemu interlevkinu-1 beta (IL-1 beta) izotipa IgG1/κ.
canal† (bisphosphonate class adverse
kanala† (neželeni učinek skupine
Canarypox virus (vCP97) ≥ 10 7.2
kanarčkov (vCP97) ≥ 10 7.2
cancel the fresh embryo transfer and cryopreserve embryos; avoid administration of hCG for luteal phase support.
opustitev prenosa svežega zarodka in krioprezervacija zarodka, neuporaba hCG za podporo lutealne faze.
cancel the fresh embryo transfer and cryopreserve embryos; avoid administration of hCG for luteal phase support.
opustitev prenosa svežih zarodkov in krioshranjevanja zarodkov; izogibanje dajanju hCG za podporo lutealni fazi.
cancer (except basal-cell carcinoma, a slow-growing type of skin cancer) or severe impairment of the heart function
raka (razen bazalnoceličnega karcinom- počasi napredujoča oblika kožnega raka), resno okvaro srčne funkcije.
cancer (except basal-cell carcinoma, a slow-growing type of skin cancer) or severe impairment of the heart function
raka (razen bazalnoceličnega karcinoma- počasi napredujoča oblika kožnega raka), resno okvaro srčne funkcije.
cancer (second primary malignancies)
rak (sekundarna primarna malignost)
cancer (such as erlotinib, gefitinib). stomach disease or heartburn (antacids such as aluminium hydroxide/magnesium hydroxide).
raku (npr. erlotinib, gefitinib), zdravljenju bolezni želodca ali zgage (antacidi, npr. aluminijev hidroksid/magnezijev hidroksid).
Cancer and non-cancerous growths of the skin
pojav rakavega ali nerakavega izrastka na koži,
Cancer cells are more sensitive to disruption by proteasome inhibitors than normal cells and, therefore, to the effects of bortezomib.
Rakave celice so občutljivejše za motnje, ki jih povzročajo zaviralci proteasoma, kot normalne celice, zato so občutljivejše tudi za bortezomib.
Cancer cells can produce proteins (PD-L1 and PD-L2) that attach to this receptor and switch off the activity of the T cells, preventing them from attacking the cancer.
PD-2), ki se vežejo na ta receptor in izklopijo delovanje celic T, tako da te ne morejo napasti rakavih celic.
Cancer cells have an increased need to produce and break down proteins due to the fact that they are multiplying rapidly.
Rakave celice imajo zaradi svojega hitrega razmnoževanje povečano potrebo po proizvodnji in razgradnji beljakovin.
cancer in your ovaries, womb or breasts.
rak jajčnika, maternice ali dojke;
cancer of the blood (leukaemia);
krvnega raka (levkemijo),
cancer of the blood cells (leukaemia)
rak krvnih celic (levkemijo),
cancer of the bone marrow (multiple myeloma)
rakavo obolenje kostnega mozga (multipli mielom),
cancer of the colon or rectum (large intestine) that is metastatic (has spread to other parts of the body), in combination with chemotherapy medicines that include a ‘fluoropyrimidine’;
raka kolona ali danke (debelega črevesa), ki je metastaziral (se je razširil v druge predele telesa), v kombinaciji z zdravili za kemoterapijo, ki vključujejo „fluoropirimidin“;
Cancer of the kidney
rak ledvic
cancer of the lymph nodes (lymphoma) (rare).
rak limfnih žlez (limfom) (redki).
Cancer of the lymph tissue (lymphoma/post-transplant lympho-proliferative disorder), combined lowering of red blood cells, white blood cells and blood platelets
rak limfnega tkiva (limfom/popresaditveni limfoproliferativni sindrom), kombinirano znižanje števila rdečih in belih krvničk ter krvnih ploščic,
cancer of the ovary, womb or breast.
raka jajčnikov, maternice ali dojke.
cancer of the rectum
rak danke
Cancer of the skin
kožni rak
cancer of white blood cells, lung cancer throat tightness
rak belih krvnih celic, pljučni rak, stiskanje v žrelu.
cancer of white blood cells, lung cancer throat tightness.
rak belih krvnih celic, pljučni rak, stiskanje v žrelu.
Cancer pain
bolečina zaradi raka
Cancer pain (G3/4: 0.6%)
bolečina zaradi raka (S 3/4: 0,6 %)
Cancer pain (G3/4: 1.2%)
bolečina zaradi raka (S 3/4: 1,2 %)
Cancer pain (G3/4: 1.2%)
Bolečina zaradi raka (S3/4: 0,6 %)
Cancer patients are more likely to suffer from blood clots if receiving erythropoietin medicines, like Retacrit (see section 4).
Pri bolnikih z rakom, ki prejemajo zdravila z eritropoetinom, kot je zdravilo Retacrit, se bolj pogosto pojavijo krvni strdki (glej poglavje 4).
Cancer patients being treated with epoetin alfa should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter.
Pri bolnikih z rakom, ki prejemajo epoetin alfa, je treba ravni hemoglobina redno meriti, dokler ni dosežena stabilna raven, potem pa v rednih časovnih intervalih.
cancer that affects the lymph system
rak, ki zajame limfni sistem
cancer that affects the lymph system;
rak, ki zajame limfni sistem;
cancer, chemotherapy, radiotherapy, corticosteroids, angiogenesis inhibitors, smoking a history of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures and poorly fitting dentures
rak, kemoterapijo, radioterapijo, kortikosteroide, zaviralce angiogeneze, kajenje, anamnezo bolezni zob, slabo ustno higieno, bolezen dlesni, invazivni zobozdravniški poseg in slabo prilegajočo zobno protezo.
cancer, chemotherapy, radiotherapy, corticosteroids, angiogenesis inhibitors, smoking a history of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures, and poorly fitting dentures
rak, kemoterapijo, radioterapijo, kortikosteroide, zaviralce angiogeneze, kajenje, anamnezo bolezni zob, slabo ustno higieno, bolezen dlesni, invazivni zobozdravniški poseg in slabo prilegajočo zobno protezo.
Cancer, co morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
očasna prisotnost raka ali drugih bolezni (na primer anemije, koagulopatije, okužbe), kajenje;
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking
očasna prisotnost raka ali drugih bolezni (na primer anemije, koagulopatije, okužbe), kajenje;
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking
očasna prisotnost raka ali drugih bolezni (npr. anemije, koagulopatije, okužbe), kajenje;
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking
rak, sočasne bolezni (npr. anemijo, koagulopatije, okužbo), kajenje,
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
očasna prisotnost raka ali drugih bolezni (na primer anemije, koagulopatije, okužbe), kajenje;
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
očasna prisotnost raka ali drugih bolezni (na primer anemije, koagulopatije, okužbe, kajenje;
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
očasna prisotnost raka ali drugih bolezni (npr. anemije, koagulopatije, okužbe), kajenje.
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
očasna prisotnost raka in drugih bolezni (npr. anemije, koagulopatije, okužbe), kajenje.
cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
rak, sočasne bolezni (npr. anemijo, koagulopatije, okužbo), kajenje,
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
rak, sočasne druge bolezni (npr. anemija, koagulopatije, infekcija), kajenje,
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
rak, sočasne druge bolezni (npr. anemija, koagulopatije, infekcija), kajenje.
Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease
Rak, sistemski eritematozni lupus, hemolitično- uremični sindrom, kronična vnetna bolezen črevesja (Crohnova bolezen ali ulcerozni kolitis) in bolezen srpastih celic
Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease.
Rak, sistemski eritematozni lupus, hemolitično uremični sindrom, kronična vnetna črevesna bolezen (Crohnova bolezen ali ulcerozni kolitis) in srpastocelična bolezen.
Cancer: Tell your doctor if the child has or has ever had lymphoma (a type of blood cancer) or any other cancer before the child is given Enbrel.
Rak: Preden bo vaš otrok prejel zdravilo Enbrel, povejte zdravniku, če ima ali je vaš otrok imel limfom (vrsta krvnega raka) ali drugo obliko raka.
Cancer: Tell your doctor if you have or have ever had lymphoma (a type of blood cancer) or any other cancer before you are given Benepali.
Rak: Preden boste prejeli zdravilo Benepali, povejte zdravniku, če imate ali ste kdaj imeli limfom (vrsta krvnega raka) ali drugo obliko raka.
Cancer: Tell your doctor if you have or have ever had lymphoma (a type of blood cancer) or any other cancer before you are given Enbrel.
Rak: Preden boste prejeli zdravilo Enbrel, povejte zdravniku, če imate ali ste kdaj imeli limfom (vrsta krvnega raka) ali drugo obliko raka.
cancer;
rak;
Cancerous white blood cells at or near the injection site (plasmacytoma).
rakave bele krvne celice na mestu injiciranja ali blizu njega (plazmacitom),
Cancers were reported in treatment-experienced and treatment-naïve patients who initiated ISENTRESS in conjunction with other antiretroviral agents.
Pri predhodno že zdravljenih in še nezdravljenih bolnikih, pri katerih je bilo uvedeno zdravljenje z zdravilom ISENTRESS v kombinaciji z drugimi protiretrovirusnimi zdravili, so poročali o pojavu rakavih obolenj.
Cancers, including skin cancer and non-cancerous growths or lumps, including skin moles
različne oblike raka, vključno s kožnim rakom in nerakavimi raščami ali bulami, vključno s kožnimi znamenji in pegami,
Cancers, other than lymphoma, have been reported in patients with a specific type of lung disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.
Pri bolnikih s posebno boleznijo pljuč, t.i. kronično obstruktivno pljučno boleznijo (KOPB), zdravljenim z nekim drugim zaviralcem TNF, so poročali o rakih, ki niso bili limfomi.
Cancidas 50 mg powder for concentrate for solution for infusion
Cancidas 50 mg prašek za koncentrat za raztopino za infundiranje kaspofungin
Cancidas 70 mg powder for concentrate for solution for infusion
Cancidas 70 mg prašek za koncentrat za raztopino za infundiranje kaspofungin
Cancidas contains a medicine called caspofungin.
Zdravilo Cancidas vsebuje zdravilno učinkovino kaspofungin.
CANCIDAS for
koncentrata zdravila
CANCIDAS for
ODMEREK
Cancidas has not been studied in pregnant women.
Uporabe zdravila Cancidas pri nosečnicah niso preučevali.
Cancidas is a sterile, white to off-white compact powder.
Zdravilo Cancidas je sterilen, bel do skoraj bel, kompakten prašek.
Cancidas is an antifungal medicine used to treat the following fungal infections in adults and children:
Cancidas je protiglivno zdravilo, ki se uporablja za zdravljenje naslednjih glivnih okužb pri odraslih in otrocih: invazivne kandidioze (vrste glivne okužbe, ki jo povzroča Candida).
CANCIDAS is formulated to provide the full labeled vial dose (50 mg) when 10 ml is withdrawn from the vial.
Zdravilo CANCIDAS je pripravljeno tako, da zagotavlja polni, na viali označeni odmerek (50 mg), če iz viale potegnete 10 ml.
CANCIDAS is formulated to provide the full labelled vial dose (70 mg) when 10 ml is withdrawn from the vial.
Zdravilo CANCIDAS je pripravljeno tako, da zagotavlja polni na viali označeni odmerek (70 mg), če iz viale potegnete 10 ml.
Cancidas is used to treat the following infections in children, adolescents and adults: serious fungal infections in your tissues or organs (called ‘invasive candidiasis’).
Zdravilo Cancidas se uporablja za zdravljenje naslednjih okužb pri otrocih, mladostnikih in odraslih: resnih glivnih okužb v vaših tkivih ali organih (imenovanih "invazivna kandidaza").
Candida infections in the oropharynx
okužbe s kandido v ustih in žrelu
Candida infections in the oropharynx
okužbe s kandido v ustnih in žrelu
Candida infections in the oropharynx, pneumonia (in COPD patients)
okužbe s kandido v ustih in žrelu, pljučnica (pri bolnikih s KOPB)
Candida infections in the oropharynx, pneumonia (in COPD patients)
okužbe s kandido v ustnih in žrelu, pljučnica (pri bolnikih s KOPB)
Candidaemia and other forms of Invasive Candidiasis
Kandidemija in druge oblike invazivne kandidoze
Candidiasis
kandidoza
Candidiasis (including oral and anal candidiasis) and fungal infection/fungal skin infections
kandidoza (vključno z oralno in analno kandidozo) in glivične okužbe/glivične okužbe kože
candidiasis and
kandidozo in
Candidiasis including oropharyngeal and vulvovaginal, Clostridium difficile colitis, fungal urinary tract infection
kandidoza, vključno z orofaringealno in vulvovaginalno, kolitis zaradi okužbe s Clostridium difficile, glivna okužba sečil
Candidiasis of mouth and throat
kandidoza ust in žrela
Candidiasis of the mouth and throat Pneumonia (in COPD patients) Bronchitis
kandidoza ustne votline in žrela pljučnica (pri bolnikih s KOPB) bronhitis
candidiasis, staphylococcal infection
kandidoza, okužba s stafilokoki
candidiasis, staphylococcal infection
kandidoza, stafilokokna okužba
Cangene Logo to be inserted
Logotip družbe Cangene
Cangrelor (N=12565)
Kangrelor (N = 12.565)
Cangrelor (N=5529)
Kangrelor (N = 5.529)
Cangrelor exhibits inhibition of activation and aggregation of platelets as shown by aggregometry (light transmission and impedance), point-of care assays, such as the VerifyNow P2Y12™ test, VASP-P and flow cytometry.
Kangrelor zavira aktivacijo in agregacijo trombocitov, kot kažejo agregometrija (svetlobna transmisija in impedanca), testi mesta oskrbe, kot so test VerifyNow P2Y12™, VASP-P in pretočna citometrija.
Cangrelor exhibits inhibition of activation and aggregation of platelets as shown by aggregometry (light transmission and impedance), point-of care assays, such as the VerifyNow P2Y12™ test, VASP-P and flow cytometry.
Kangrelor zavira aktivacijo in agregacijo trombocitov, kot kažejo agregometrija (svetlobna transmisija in impedanca), testi mesta oskrbe, kot so test VerifyNow P2Y12™, VASP-P in tekoča citometrija.
Cangrelor has not been evaluated in a paediatric population (see section 4.2 and section 5.1).
Kangrelorja niso ocenili pri pediatrični populaciji (glejte poglavje 4.2 in poglavje 5.1).
Cangrelor is contraindicated in patients with any history of stroke/TIA, (see section 4.3 and section 4.8).
Kangrelor je kontraindiciran pri bolnikih z možgansko kapjo/TIA v anamnezi, (glejte poglavje 4.3 in poglavje 4.8).
Cangrelor N=5462
Kangrelor N = 5.462
Cangrelor N=5470
Kangrelor N = 5.470
Canigen L4 Suspension for injection for dogs
Canigen L4 suspenzija za injiciranje za pse
Canigen L4, suspension for injection for dogs
Canigen L4, suspenzija za injiciranje za pse
CaniLeish
Vsaj100 μg
CaniLeish contains an ‘adjuvant’ (a highly purified fraction of Quillaja saponaria) to enhance the immune response.
Cepivo CaniLeish vsebuje „adjuvans“ (prečiščeni ekstrakt Quillaja saponaria), ki okrepi imunski odziv.
CaniLeish is to be used only in ‘leishmania-negative’ dogs.
Cepivo CaniLeish se lahko uporablja samo pri psih, ki so negativni na parazit Leishmania.
CaniLeish lyophilisate and solvent for suspension for injection for dogs
CaniLeish liofilizat in vehihel –suspenzija za injiciranje za pse
CaniLeish lyophilisate and solvent for suspension for injection for dogs
Liofilizat in vehihel –suspenzija za injiciranje
canine adenovirus type 1, which causes an acute liver infection that may produce signs of jaundice (yellowing of the skin and eyes);
pasjim adenovirusom tipa 1, ki povzroča akutno okužbo jeter, pri kateri se lahko pojavijo znaki zlatenice (porumenelost kože in oči);
canine adenovirus type 1, which causes an acute liver infection that may produce signs of jaundice (yellowing of the skin and eyes); canine parvovirus disease, an infection that may severely affect puppies, resulting in lethargy, fever, vomiting and bloody diarrhoea;
pasjim adenovirusom tipa 1, ki povzroča akutno okužbo jeter, pri kateri se lahko pojavijo znaki zlatenice (porumenelost kože in oči); boleznijo, ki jo povzroča pasji parvovirus, tj. okužbo, ki lahko močno prizadene pasje mladiče in povzroči letargijo, povišano telesno temperaturo, bruhanje in krvavo drisko;
Canine distemper virus, strain CDV Bio 11/A 103.1 TCID50* 105.1 TCID50 Canine adenovirus Type 2, strain CAV-2 Bio 13 103.6 TCID50* 105.3 TCID50 Canine parvovirus Type 2b, strain CPV-2b Bio 12/B 104.3 TCID50* 106.6 TCID50 Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 103.1 TCID50* 105.1 TCID50
Virus pasje kuge, sev CDV Bio 11/A 103,1 TCID50* 105,1 TCID50 Virus pasjega adenovirusa tipa 2, sev CAV-2 Bio 13 103,6 TCID50* 105,3 TCID50 Virus pasjega parvovirusa tipa 2b, sev CPV-2b Bio 12/B 104,3 TCID50* 106,6 TCID50 Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15 103,1 TCID50* 105,1 TCID50
Canine distemper virus, strain CDV Bio 11/A 103.1 TCID50* 105.1 TCID50 Canine adenovirus type 2, strain CAV-2 Bio 13 103.6 TCID50* 105.3 TCID50 Canine parvovirus type 2b, strain CPV-2b Bio 12/B 104.3 TCID50* 106.6 TCID50 Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 TCID50* 105.1 TCID50.
Virus pasje kuge, sev CDV Bio 11/A 103,1 TCID50* 105,1 TCID50 Virus pasjega adenovirusa tipa 2, sev CAV-2 Bio 13 103,6 TCID50* 105,3 TCID50 Virus pasjega parvovirusa tipa 2b, sev CPV-2b Bio 12/B 104,3 TCID50* 106,6 TCID50 Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15 103,1 TCID50* 105,1 TCID50
canine distemper, an infectious disease which is sometimes called hard pad since dogs can develop thickening of the skin on the foot pads, as well as runny nose, cough, fever, vomiting and diarrhoea, excessive salivation and in some cases fits;
pasjo kugo, tj. infekcijsko boleznijo, ki jo včasih imenujemo tudi bolezen trdih blazinic, saj se lahko pri psih pojavi odebeljena koža na blazinicah na šapah, poleg tega pa tudi izcedek iz smrčka, kašelj, povišana telesna temperatura, bruhanje in driska, čezmerno slinjenje ter v nekaterih primerih krči;
canine distemper, an infectious disease which is sometimes called ‘hard pad’ since dogs can develop thickening of the skin on the foot pads, as well as runny nose, cough, fever, vomiting, diarrhoea, excessive salivation and in some cases fits;
pasjo kugo, tj. infekcijsko boleznijo, ki jo včasih imenujemo tudi bolezen trdih blazinic, saj se lahko pri psih pojavi odebeljena koža na blazinicah na šapah, poleg tega pa tudi izcedek iz smrčka, kašelj, povišana telesna temperatura, bruhanje, driska, čezmerno slinjenje ter v nekaterih primerih krči;
Canine distemper, canine adenovirus, canine parvovirosis and canine parainfluenza virus vaccine (live attenuated)
cepivo proti pasji kugi, pasjemu adenovirusu, pasji parvovirozi in virusu pasje parainfluence (živo, atenuirano)